RadioMedix & Curium Announce Detectnetᵀᴹ (copper Cu 64 dotatate injection) Inclusion on NCCN Guidelines®

Louis, MO, May 05, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that Detectnet is now included in the National Comprehensive Cancer Network\xc2\xae (NCCN) Clinical Practice Guidelines in Oncology \xe2\x80\x93 Neuroendocrine and Adrenal Tumors, version 1.2021 for the evaluation of neuroendocrine tumors (NETs).